Medical Affairs Reputations (EU5) [Cancer Pain]
There’s plenty of room for teams to improve. Can your team seize the opportunity?
The medical oncologists we surveyed say that medical affairs teams for cancer pain drugs turned in a disappointing performance in the past 6 months. Their ratings on individual services barely crept above neutral, and they’re failing to deliver the information doctors need. Nevertheless, doctors are open to more frequent interactions, so there’s plenty of opportunity for a motivated team to start delivering the goods, and leap ahead of the competition.
Find out what your team gets right, and where it’s going wrong in Medical Affairs Reputations: Cancer Pain (EU5).
Comparing 7 major cancer pain treatments from Kyowa Kirin, Mundipharma/Napp, Takeda, and Teva, this report reveals:
Top Takeaways
Top Takeaways
Developed with the help of medical affairs specialists, this report gives you an in-depth comparison of 7 medical affairs teams—answering important questions like:
What do doctors need?
We surveyed 150 medical oncologists from the EU5 (France, Italy, Germany, Spain and the UK) —chosen from the largest community of validated physicians in the world
All respondents:
MONEY BACK GUARANTEE!
At FirstWord, we stand behind our reports. If you're not completely satisfied, we’ll refund your money. Guaranteed.
About FirstWord
FirstWord is an innovative industry intelligence leader serving over 240,000 Pharma and MedTech professionals worldwide. FirstWord offers a range of products and services designed to help your company gain a competitive edge by making key business decisions with speed and confidence.
FirstWord Pharma PLUS is a personalised and comprehensive intelligence service delivering up-to-the-minute pharma news, insight, analysis and expert views of importance to your company’s success.
FirstWord Reports deliver timely, need-to-know intelligence about your products, your competitors and your markets. Covering biosimilars, market access, medical affairs, sales & marketing, technology and therapy areas, FirstWord Reports provide expert views and intelligence on the challenges facing pharma today.
The medical oncologists we surveyed say that medical affairs teams for cancer pain drugs turned in a disappointing performance in the past 6 months. Their ratings on individual services barely crept above neutral, and they’re failing to deliver the information doctors need. Nevertheless, doctors are open to more frequent interactions, so there’s plenty of opportunity for a motivated team to start delivering the goods, and leap ahead of the competition.
Find out what your team gets right, and where it’s going wrong in Medical Affairs Reputations: Cancer Pain (EU5).
Comparing 7 major cancer pain treatments from Kyowa Kirin, Mundipharma/Napp, Takeda, and Teva, this report reveals:
- How doctors rate your team overall, and on 12 key medical affairs services.
- Which medical affairs services are most important, and what you can do to improve them.
- How, and how often doctors want to meet with your team.
Top Takeaways
Top Takeaways
- Humdrum results: Performance and satisfaction ratings for individual medical affairs services are neutral to slightly positive.
- One team leads for overall quality of interactions: But not by much. 3 other teams are competing for 3rd place, while another 3 are competing for 5th.
- Specific improvements needed: 5 of the surveyed teams need to improve 1 or 2 specific services.
- Nearly 40% of doctors say teams could do a better job of providing information: They identified 4 ways teams can improve, and highlighted the type of information they want.
- Doctors are very unhappy with one team: It earns the lowest performance and satisfaction ratings for almost every medical affairs service.
- Teams may be under-communicating: Doctors tend to want to hear from teams more often than teams are contacting them.
- Abstral (fentanyl sublingual; Kyowa Kirin)
- Actiq (fentanyl transmucosal; Teva)
- Effentora (fentanyl buccal; Teva)
- Instanyl (fentanyl intranasal; Takeda)
- PecFent (fentanyl intranasal; Kyowa Kirin)
- OxyContin (oxycodone CII; Mundipharma/Napp)
- OxyNorm (oxycodone IR; Mundipharma/Napp)
Developed with the help of medical affairs specialists, this report gives you an in-depth comparison of 7 medical affairs teams—answering important questions like:
What do doctors need?
- How, and how often are doctors using your medical affairs team?
- What services do they consider most important?
- How often should you contact them? What channels are best?
- How memorable are your team’s interactions with doctors?
- How do doctors rank your team for performance and satisfaction in 12 key areas?
- How does your team compare to the competition—in each area, and overall?
- Are you delivering the services that are most important to doctors?
- Where do you need to improve?
- How can your team enhance its services?
We surveyed 150 medical oncologists from the EU5 (France, Italy, Germany, Spain and the UK) —chosen from the largest community of validated physicians in the world
All respondents:
- Have been practicing for between 3 and 35 years
- See at least 5 patients with cancer pain in a typical month
- Devote at least 50% of their time to direct patient care
- Have interacted with at least one listed product’s medical affairs team in the past 6 months.
MONEY BACK GUARANTEE!
At FirstWord, we stand behind our reports. If you're not completely satisfied, we’ll refund your money. Guaranteed.
About FirstWord
FirstWord is an innovative industry intelligence leader serving over 240,000 Pharma and MedTech professionals worldwide. FirstWord offers a range of products and services designed to help your company gain a competitive edge by making key business decisions with speed and confidence.
FirstWord Pharma PLUS is a personalised and comprehensive intelligence service delivering up-to-the-minute pharma news, insight, analysis and expert views of importance to your company’s success.
FirstWord Reports deliver timely, need-to-know intelligence about your products, your competitors and your markets. Covering biosimilars, market access, medical affairs, sales & marketing, technology and therapy areas, FirstWord Reports provide expert views and intelligence on the challenges facing pharma today.
1. OBJECTIVES, SURVEY METHODOLOGY AND SAMPLING, PRODUCTS INCLUDED IN THE SURVEY, EXECUTIVE SUMMARY
2. CURRENT STATUS OF INTERACTIONS WITH DIFFERENT MEDICAL AFFAIRS TEAMS
2.1 Interactions in the past 6 months with Medical Affairs teams for each product
2.2 Current frequency of interactions with medical affair teams for each product
3. COMPETITIVE EVALUATION OF MEDICAL AFFAIRS TEAMS PERFORMANCE ON VARIOUS ATTRIBUTES
3.1 Evaluation of overall quality of interactions with Medical Affairs teams for each product
3.2 Attribute importance of Medical Affairs teams roles to physicians’ practice
3.3 EdgeMap analysis – Competitive evaluation on Medical Affairs teams performance on attributes
3.4 Competitive evaluation of physicians satisfaction of interaction with Medical Affairs teams
3.5 Need-Gap analysis by product
4. PREFERRED INTERACTION MEDIA, FREQUENCY, AND SUGGESTIONS FOR IMPROVEMENT
4.1Preferred interaction media and frequency, and suggestions for improvement
5. APPENDIX
2. CURRENT STATUS OF INTERACTIONS WITH DIFFERENT MEDICAL AFFAIRS TEAMS
2.1 Interactions in the past 6 months with Medical Affairs teams for each product
2.2 Current frequency of interactions with medical affair teams for each product
3. COMPETITIVE EVALUATION OF MEDICAL AFFAIRS TEAMS PERFORMANCE ON VARIOUS ATTRIBUTES
3.1 Evaluation of overall quality of interactions with Medical Affairs teams for each product
3.2 Attribute importance of Medical Affairs teams roles to physicians’ practice
3.3 EdgeMap analysis – Competitive evaluation on Medical Affairs teams performance on attributes
3.4 Competitive evaluation of physicians satisfaction of interaction with Medical Affairs teams
3.5 Need-Gap analysis by product
4. PREFERRED INTERACTION MEDIA, FREQUENCY, AND SUGGESTIONS FOR IMPROVEMENT
4.1Preferred interaction media and frequency, and suggestions for improvement
5. APPENDIX
